Dose-Response · 2020 · 11 citations · 33 references
MedicineOncologyPathologyCancer ImmunologyImmunopathologyTumor ImmunologyCancer BiomarkersCancer Survival AnalysisImmuno-oncology BiomarkersLymphoid NeoplasmsC-reactive Protein TestingCox RegressionNatural Killer T-cell LymphomaNatural Killer-cell LymphomaPredictive PerformancePretreatmentPrognostic PredictionStratification Analysis
Objective: The prognostic value of C-reactive protein to albumin ratio (CAR) has been identified in several cancers but not in extranodal natural killer T-cell lymphoma (ENKTL) as yet. We aimed to evaluate the prognostic value of CAR in ENKTL. Methods: A retrospective study with 246 patients with ENKTL was performed to determine the prognostic value of pretreatment CAR and examine the prognostic performance of CAR incorporating with International Prognostic Index (IPI) or natural killer/T-cell lymphoma prognostic index (NKPI) by nomogram. Results: The Cox regression analyses showed that high CAR (>0.3) independently predicted unfavorable progression-free survival (PFS, P = .011) and overall survival (OS, P = .012). In the stratification analysis, the CAR was able to separate patients into different prognoses regarding both OS and PFS in Ann Arbor stage I+II as well as III+IV, IPI score 0 to 1, and NKPI score 1 to 2 subgroups (all P < .05). Additionally, the predictive accuracy of the IPI-based nomogram incorporating CAR, albumin to globulin ratio (AGR), and IPI for OS and PFS appeared to be lower than the NKPI-based nomogram incorporating CAR, age, AGR, extranodal site, and NKPI. Conclusion: Pretreatment CAR is a simple and easily accessible parameter for independently predicting OS and PFS in patients with ENKTL.
33
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
New England Journal of Medicine · 1993 · 5K citations · Full text
Medicine, Oncology, Chemotherapy +15
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp, David P. Harrington, J R Anderson et al. · 1993 · 3.5K citations
Medicine, Oncology, Chemotherapy +15